Drawing for LUMJEVI

USPTO serial 88000919

LUMJEVI

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
Examiner
PAPALE, LISA ANNE
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with LUMJEVI?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Bruce W. Longbottom

Bruce W. Longbottom ELI LILLY AND COMPANYLILLY CORPORATE CENTERINDIANAPOLIS, IN 46285UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, hypoglycemia, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases and of oncology and of painACTIVE

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Dec 21, 2020MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Dec 21, 2020ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 11, 2020EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 9, 2020EX3GSOU EXTENSION 3 GRANTED
Apr 9, 2020EXT3SOU EXTENSION 3 FILED
Apr 9, 2020EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 17, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 15, 2019EX2GSOU EXTENSION 2 GRANTED
Oct 15, 2019EXT2SOU EXTENSION 2 FILED
Oct 15, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 11, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 9, 2019EX1GSOU EXTENSION 1 GRANTED
Apr 9, 2019EXT1SOU EXTENSION 1 FILED
Apr 9, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 20, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 25, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 25, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 5, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 23, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER
Aug 23, 2018DOCKASSIGNED TO EXAMINER
Jun 20, 2018NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 18, 2018NWAPNEW APPLICATION ENTERED

Frequently asked questions

Related guidance